https://statehealthcompare.shadac.org/table/4/health-insurance-co...

https://statehealthcompare.shadac.org/table/4/health-insurance-coverage-type-by-age#1/5,4,1,10,86,9,8,6,3,12,13,20,25,14,21,22,23,24,11/37/7,8

Very rough internet search concurs with DAngel.

Glaucoma not just affects elderly though but keeps being the majority.

My question for both sides of the table here in HC, is what would it take to re-rate this company to a P/S of 4.0 for instance? We usually have an answer from 007, but would like to hear from others _less positive_ than 007 with their reasoning.

Yes, we know that the revenue is decreasing in the short term, but it is basically staying at the same P/S that it was a year ago... with a better product than two years ago (nobody can take that away from EYE) growth potential in Asia (which other companies don't seem to have) and a possible big partnership in the cards, without counting other confidential developments they might have.

Why is it at a P/S of 1.5 still? why? why?

I'm way too exposed to EYE now, and painfully in the red, but I still believe in the company.

GLTAH